Boundless Bio, Inc. (BOLD) stock
BOLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.46+0.00 (0.00%)
Close on Nov 12, 2026Market cap $55.96MP/E –Yield –
Boundless Bio r&d expenses
Research and development expenses are spending on new products and technology.
Boundless Bio's R&D Expenses for the twelve months ending Sep 30, 2026 was $34.96M, down 27.7% year over year. For fiscal 2025 it was $44.85M, down 18.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.85M | -18.9% |
| FY2024 | Dec 31, 2024 | $55.27M | +29.6% |
| FY2023 | Dec 31, 2023 | $42.64M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.44M | -86.5% |
| Q2 FY2026 | Jun 30, 2026 | $13.97M | +14.4% |
| Q1 FY2026 | Mar 31, 2026 | $9.73M | -19.8% |
| Q4 FY2025 | Dec 31, 2025 | $9.82M | -26.3% |
| Q3 FY2025 | Sep 30, 2025 | $10.67M | -24.2% |
| Q2 FY2025 | Jun 30, 2025 | $12.22M | -17.1% |
| Q1 FY2025 | Mar 31, 2025 | $12.14M | -7.5% |
| Q4 FY2024 | Dec 31, 2024 | $13.31M | +27.8% |
| Q3 FY2024 | Sep 30, 2024 | $14.09M | +21.0% |
| Q2 FY2024 | Jun 30, 2024 | $14.74M | +33.0% |
| Q1 FY2024 | Mar 31, 2024 | $13.13M | +38.2% |
| Q4 FY2023 | Dec 31, 2023 | $10.41M | – |
| Q3 FY2023 | Sep 30, 2023 | $11.65M | – |
| Q2 FY2023 | Jun 30, 2023 | $11.08M | – |
| Q1 FY2023 | Mar 31, 2023 | $9.50M | – |
See a number that looks wrong?